WHO Has Just Approved These Two Treatments For Covid-19: New Breakthrough?
With the number of Covid-19 cases rising across the country and globally, pharmaceutical companies across the globe are striving to launch different medications, vaccines and even capsules to tackle the Omicron variant.
According to a study conducted by the University of Hong Kong, Omicron replicates about 70 times faster than the delta variant or even the original Covid variant, in the human bronchus.
Trak.in has covered in detail about this. Read it here.
On Friday, the coveted World Health Organization gave approval to two new forms of Covid-19 treatments, adding to the existing list of medications and vaccines to tackle the intensity of the virus.
WHO on Two New Covid-19 Treatments
The Omicron variant of Covid-19 pandemic is far more transmissible than the virus’ original structure or other variants like Delta.
WHO has given the green signal to two new treatments for Covid-19, as recommended in the British Medical Journal, BMJ.
According to the recommendation, the Janus kinase (JAK) inhibitor baricitinib, which is also used to treat rheumatoid arthritis, is strongly recommended for patients with severe or critical covid-19 in combination with corticosteroids, an expert group from the WHO has written in the journal.
WHO’s Guideline Development Group found moderate certainty evidence that baricitinib improved survival and reduced the need for ventilation, with no observed increase in adverse effects, cites the report from BMJ.
Besides, experts from the health organization have also recommended treating the infection using the synthetic antibody treatment Sotrovimab, for those people with lower Covid intensity but at higher ‘at-risk’ disposition, like people with immunodeficiencies or chronic diseases like diabetes, and the elderlies.
Sotrovimab’s benefits for people not at risk of hospitalization were deemed insignificant and the WHO said its effectiveness against new variants like Omicron was “still uncertain”, states a NDTV report.
Besides, Arthritis drugs tocilizumab and sarilumab, endorsed by the WHO in July are IL-6 inhibitors and keep in check the immune system’s overreaction to the Covid-19 virus.